Citations (39)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Tony Reiman, Kerry J. Savage, Michael Crump, Matthew C. Cheung, David MacDonald, Rena Buckstein, Stephen Couban, Eugenia Piliotis, Kevin Imrie, David Spaner, Sudeep Shivakumar, John Kuruvilla, Diego Villa, Lois E. Shepherd, Tanya Skamene, Chad Winch, Bingshu E. Chen & Annette E. Hay. (2019) A phase I study of romidepsin, gemcitabine, dexamethasone and cisplatin combination therapy in the treatment of peripheral T-cell and diffuse large B-cell lymphoma; the Canadian cancer trials group LY.15 study†. Leukemia & Lymphoma 60:4, pages 912-919.
Read now
Read now
Adam Petrich & Chadi Nabhan. (2016) Use of class I histone deacetylase inhibitor romidepsin in combination regimens. Leukemia & Lymphoma 57:8, pages 1755-1765.
Read now
Read now
Articles from other publishers (37)
Nasreddine El Omari, Learn-Han Lee, Saad Bakrim, Hafiz A. Makeen, Hassan A. Alhazmi, Syam Mohan, Asaad Khalid, Long Chiau Ming & Abdelhakim Bouyahya. (2023) Molecular mechanistic pathways underlying the anticancer therapeutic efficiency of romidepsin. Biomedicine & Pharmacotherapy 164, pages 114774.
Crossref
Crossref
Romain Pacaud, Jose Garcia, Scott Thomas & Pamela N. Munster. 2023. Handbook of Epigenetics. Handbook of Epigenetics
793
819
.
Asmaa Elrakaybi, Dietrich A. Ruess, Michael Lübbert, Michael Quante & Heiko Becker. (2022) Epigenetics in Pancreatic Ductal Adenocarcinoma: Impact on Biology and Utilization in Diagnostics and Treatment. Cancers 14:23, pages 5926.
Crossref
Crossref
Xue-Song Xiang, Peng-Cheng Li, Wen-Quan Wang & Liang Liu. (2022) Histone deacetylases: A novel class of therapeutic targets for pancreatic cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1877:1, pages 188676.
Crossref
Crossref
Sadiya Khwaja, Kapil Kumar, Ranjana Das & Arvind Singh Negi. (2021) Microtubule associated proteins as targets for anticancer drug development. Bioorganic Chemistry 116, pages 105320.
Crossref
Crossref
Joyce K. Thompson & Filip Bednar. (2021) Clinical Utility of Epigenetic Changes in Pancreatic Adenocarcinoma. Epigenomes 5:4, pages 20.
Crossref
Crossref
Pawat Pattarawat, Jessica T. Hunt, Jacob Poloway, Collin J. Archibald & Hwa-Chain Robert Wang. (2021) A triple combination gemcitabine + romidepsin + cisplatin to effectively control triple-negative breast cancer tumor development, recurrence, and metastasis. Cancer Chemotherapy and Pharmacology 88:3, pages 415-425.
Crossref
Crossref
Anton Frühauf & Franz-Josef Meyer-Almes. (2021) Non-Hydroxamate Zinc-Binding Groups as Warheads for Histone Deacetylases. Molecules 26:17, pages 5151.
Crossref
Crossref
Robert Jenke, Nina Reßing, Finn K. Hansen, Achim Aigner & Thomas Büch. (2021) Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives. Cancers 13:4, pages 634.
Crossref
Crossref
Stephen Booth & Graham Collins. (2020) Epigenetic targeting in lymphoma. British Journal of Haematology 192:1, pages 50-61.
Crossref
Crossref
Loredana Cappellacci, Diego R. Perinelli, Filippo Maggi, Mario Grifantini & Riccardo Petrelli. (2020) Recent Progress in Histone Deacetylase Inhibitors as Anticancer Agents. Current Medicinal Chemistry 27:15, pages 2449-2493.
Crossref
Crossref
Basheerulla Shaik, Tabassum Zafar & Satya P. Gupta. (2020) Recent Studies on HDAC Inhibitors Acting against Prostate Cancer. Current Enzyme Inhibition 16:1, pages 74-89.
Crossref
Crossref
Aubrey L. Miller, Patrick L. Garcia & Karina J. Yoon. (2020) Developing effective combination therapy for pancreatic cancer: An overview. Pharmacological Research 155, pages 104740.
Crossref
Crossref
Zoe Weydert, Madhu Lal-Nag, Lesley Mathews-Greiner, Christoph Thiel, Henrik Cordes, Lars Küpfer, Patrick Guye, Jens M. Kelm & Marc Ferrer. (2020) A 3D Heterotypic Multicellular Tumor Spheroid Assay Platform to Discriminate Drug Effects on Stroma versus Cancer Cells. SLAS Discovery 25:3, pages 265-276.
Crossref
Crossref
Richard S. Laschanzky, Lisa E. Humphrey, Jihyun Ma, Lynette M. Smith, Thomas J. Enke, Surendra K. Shukla, Aneesha Dasgupta, Pankaj K. Singh, Gillian M. Howell, Michael G. Brattain, Quan P. Ly, Adrian R. Black & Jennifer D. Black. (2019) Selective Inhibition of Histone Deacetylases 1/2/6 in Combination with Gemcitabine: A Promising Combination for Pancreatic Cancer Therapy. Cancers 11:9, pages 1327.
Crossref
Crossref
Annie A. Wu, Elizabeth Jaffee & Valerie Lee. (2019) Current Status of Immunotherapies for Treating Pancreatic Cancer. Current Oncology Reports 21:7.
Crossref
Crossref
Nikolaos Garmpis, Christos Damaskos, Anna Garmpi, Serena Valsami & Dimitrios Dimitroulis. 2019. Pharmacoepigenetics. Pharmacoepigenetics
501
521
.
Rekha Sangwan, Remya Rajan & Pintu Kumar Mandal. (2018) HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors. European Journal of Medicinal Chemistry 158, pages 620-706.
Crossref
Crossref
Emily Chan, E. Gabriela Chiorean, Peter J. O’Dwyer, Nashat Y. Gabrail, Thierry Alcindor, Diane Potvin, Richard Chao & Herbert Hurwitz. (2017) Phase I/II study of mocetinostat in combination with gemcitabine for patients with advanced pancreatic cancer and other advanced solid tumors. Cancer Chemotherapy and Pharmacology 81:2, pages 355-364.
Crossref
Crossref
Jesse J. McClure, Xiaoyang Li & C. James Chou. 2018.
183
211
.
Emanuely Silva Chrun, Filipe Modolo & Filipe Ivan Daniel. (2017) Histone modifications: A review about the presence of this epigenetic phenomenon in carcinogenesis. Pathology - Research and Practice 213:11, pages 1329-1339.
Crossref
Crossref
Shane V. Hegarty, Katie L. Togher, Eimear O’Leary, Franziska Solger, Aideen M. Sullivan & Gerard W. O’Keeffe. (2017) Romidepsin induces caspase-dependent cell death in human neuroblastoma cells. Neuroscience Letters 653, pages 12-18.
Crossref
Crossref
Dietrich A. Ruess, Kivanc Görgülü, Sonja M. Wörmann & Hana Algül. (2017) Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts. Drugs & Aging 34:5, pages 331-357.
Crossref
Crossref
Jeenah Park, Manuela Terranova-Barberio, Allison Y. Zhong, Scott Thomas & Pamela N. Munster. 2017. Handbook of Epigenetics. Handbook of Epigenetics
605
621
.
Cinzia Pellegrini, Anna Dodero, Annalisa Chiappella, Federico Monaco, Debora Degl’Innocenti, Flavia Salvi, Umberto Vitolo, Lisa Argnani, Paolo Corradini & Pier Luigi Zinzani. (2016) A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients. Journal of Hematology & Oncology 9:1.
Crossref
Crossref
Gabriele Giacomo Schiattarella, Anna Sannino, Evelina Toscano, Fabio Cattaneo, Bruno Trimarco, Giovanni Esposito & Cinzia Perrino. (2016) Cardiovascular effects of histone deacetylase inhibitors epigenetic therapies: Systematic review of 62 studies and new hypotheses for future research. International Journal of Cardiology 219, pages 396-403.
Crossref
Crossref
C.A. Zahnow, M. Topper, M. Stone, T. Murray-Stewart, H. Li, S.B. Baylin & R.A. CaseroJr.Jr.. 2016.
55
111
.
David E. Gerber, David A. Boothman, Farjana J. Fattah, Ying Dong, Hong Zhu, Rachel A. Skelton, Laurin L. Priddy, Peggy Vo, Jonathan E. Dowell, Venetia Sarode, Richard Leff, Claudia Meek, Yang Xie & Joan H. Schiller. (2015) Phase 1 study of romidepsin plus erlotinib in advanced non-small cell lung cancer. Lung Cancer 90:3, pages 534-541.
Crossref
Crossref
Saira R. Ali, Karen J. Humphreys, Ross A. McKinnon & Michael Z. Michael. (2015) Impact of Histone Deacetylase Inhibitors on microRNA Expression and Cancer Therapy: A Review. Drug Development Research 76:6, pages 296-317.
Crossref
Crossref
Rosaria BenedettiMariarosaria ConteLucia Altucci. (2015) Targeting Histone Deacetylases in Diseases: Where Are We?. Antioxidants & Redox Signaling 23:1, pages 99-126.
Crossref
Crossref
Madhusoodanan Mottamal, Shilong Zheng, Tien Huang & Guangdi Wang. (2015) Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents. Molecules 20:3, pages 3898-3941.
Crossref
Crossref
Geoffrey Kozak, Fernando F. Blanco & Jonathan R. Brody. (2015) Novel Targets in Pancreatic Cancer Research. Seminars in Oncology 42:1, pages 177-187.
Crossref
Crossref
Jasmijn G.M. van Kampen, Monica A.J. Marijnissen-van Zanten, Femke Simmer, Winette T.A. van der Graaf, Marjolijn J.L. Ligtenberg & Iris D. Nagtegaal. (2014) Epigenetic targeting in pancreatic cancer. Cancer Treatment Reviews 40:5, pages 656-664.
Crossref
Crossref
Wei-Jan Huang, Yen-An Tang, Mei-Yu Chen, Ying-Jan Wang, Fu-Han Hu, Tseng-Wei Wang, Shi-Wei Chao, Hui-Wen Chiu, Ya-Ling Yeh, Hsin-Yi Chang, Hsueh-Fen Juan, Pinpin Lin & Yi-Ching Wang. (2014) A histone deacetylase inhibitor YCW1 with antitumor and antimetastasis properties enhances cisplatin activity against non-small cell lung cancer in preclinical studies. Cancer Letters 346:1, pages 84-93.
Crossref
Crossref
Kristina Keller & Manfred Jung. 2014. Epigenetic Therapy of Cancer. Epigenetic Therapy of Cancer
227
255
.
Angie L. McGraw. (2013) Romidepsin for the treatment of T-cell lymphomas. American Journal of Health-System Pharmacy 70:13, pages 1115-1122.
Crossref
Crossref
Alexandra MR Marsh, Ruth Narramore, Keith Chapple, Alan J Lobo, Jonathan RL Wild & Bernard M Corfe. (2013) Histone deacetylase inhibitors: recent outcomes from clinical trials and the implications for oncology treatment approaches. Clinical Investigation 3:6, pages 571-594.
Crossref
Crossref